JP2023552827A5 - - Google Patents

Info

Publication number
JP2023552827A5
JP2023552827A5 JP2023534948A JP2023534948A JP2023552827A5 JP 2023552827 A5 JP2023552827 A5 JP 2023552827A5 JP 2023534948 A JP2023534948 A JP 2023534948A JP 2023534948 A JP2023534948 A JP 2023534948A JP 2023552827 A5 JP2023552827 A5 JP 2023552827A5
Authority
JP
Japan
Prior art keywords
nitrogen
sulfur
oxygen
independently selected
heteroatoms independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023534948A
Other languages
English (en)
Japanese (ja)
Other versions
JP7832945B2 (ja
JP2023552827A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062640 external-priority patent/WO2022125790A1/en
Publication of JP2023552827A publication Critical patent/JP2023552827A/ja
Publication of JP2023552827A5 publication Critical patent/JP2023552827A5/ja
Application granted granted Critical
Publication of JP7832945B2 publication Critical patent/JP7832945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023534948A 2020-12-09 2021-12-09 Irak分解剤およびそれらの使用 Active JP7832945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063123330P 2020-12-09 2020-12-09
US63/123,330 2020-12-09
PCT/US2021/062640 WO2022125790A1 (en) 2020-12-09 2021-12-09 Irak degraders and uses thereof

Publications (3)

Publication Number Publication Date
JP2023552827A JP2023552827A (ja) 2023-12-19
JP2023552827A5 true JP2023552827A5 (cg-RX-API-DMAC7.html) 2024-12-17
JP7832945B2 JP7832945B2 (ja) 2026-03-18

Family

ID=81973811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534948A Active JP7832945B2 (ja) 2020-12-09 2021-12-09 Irak分解剤およびそれらの使用

Country Status (13)

Country Link
US (2) US20230096599A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259128A4 (cg-RX-API-DMAC7.html)
JP (1) JP7832945B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230130179A (cg-RX-API-DMAC7.html)
CN (1) CN116669722A (cg-RX-API-DMAC7.html)
AR (1) AR124294A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021396308A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200608A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006818A2 (cg-RX-API-DMAC7.html)
IL (1) IL303458A (cg-RX-API-DMAC7.html)
MX (1) MX2023006719A (cg-RX-API-DMAC7.html)
TW (1) TW202237601A (cg-RX-API-DMAC7.html)
WO (1) WO2022125790A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
EP4393922A4 (en) * 2021-08-23 2026-01-28 Leadingtac Pharmaceutical Shaoxing Co Ltd IRAK4 DEGRADATION AGENT, ITS PREPARATION PROCESS AND ITS USE
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses
WO2024020084A1 (en) * 2022-07-20 2024-01-25 Bristol-Myers Squibb Company Heteroaryl compounds as ligand directed degraders of irak4
KR20260048566A (ko) * 2023-07-13 2026-04-10 인크레랜드 방향족 화합물, 이를 포함하는 약제학적 조성물 및 이의 용도
EP4759807A1 (en) 2023-08-11 2026-06-17 Shenzhen Zhongge Biological Technology Co., Ltd. Proteolysis targeting chimera compound for degrading irak4 and use thereof
EP4775569A1 (en) * 2023-09-08 2026-07-15 The Global Health Drug Discovery Institute 3cl protease inhibitor for treating or preventing coronavirus infections and use thereof
WO2025108406A1 (zh) * 2023-11-22 2025-05-30 广东东阳光药业股份有限公司 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途
WO2025168131A1 (zh) * 2024-02-08 2025-08-14 清华大学 一种多靶降解剂及其用途
WO2026136763A1 (en) 2024-12-19 2026-06-25 Bristol-Myers Squibb Company Genetic predictor for il18 driven disease
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201728592A (zh) * 2012-01-10 2017-08-16 林伯士艾瑞斯公司 Irak抑制劑及其用途
HK1254469A1 (zh) * 2015-06-26 2019-07-19 Dana Farber Cancer Institute, Inc. 稠合双环嘧啶衍生物及其用途
WO2017007612A1 (en) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017185031A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
US11065231B2 (en) * 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US12454520B2 (en) * 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
AU2019389174A1 (en) * 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP7874541B2 (ja) * 2019-09-16 2026-06-16 ノバルティス アーゲー 接着分解剤及びその使用方法
WO2021188948A1 (en) * 2020-03-19 2021-09-23 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof

Similar Documents

Publication Publication Date Title
IL315310A (en) Irak degraders and uses thereof
Jung et al. Antitumor activity of novel deoxoartemisinin monomers, dimers, and trimer
ES3002745T3 (en) Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
AR124294A1 (es) Degradadores de irak y sus usos
AR117102A1 (es) Inhibidores de arg1 y/o arg2
JP2016505012A5 (cg-RX-API-DMAC7.html)
JP2014503504A (ja) ミトコンドリアの電子伝達系の複合体iiiの活性の阻害剤、及び疾患を治療するためのその使用
JP2013506715A5 (cg-RX-API-DMAC7.html)
JP2013529196A5 (cg-RX-API-DMAC7.html)
RU2011124304A (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
ATE336991T1 (de) Bis(thio-hydrazid amid) verbindungen zur behandlung von mehrfach resistenten krebs
JP2022176252A (ja) キレート化されたpsma阻害剤
JP2018513875A5 (cg-RX-API-DMAC7.html)
RU2016150326A (ru) Производные изоиндолина для применения в лечении вирусной инфекции
RU2017132330A (ru) Соли производного хиназолина и способ их получения
ES3003782T3 (en) Substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
JP2024528986A5 (cg-RX-API-DMAC7.html)
JP2010510216A5 (cg-RX-API-DMAC7.html)
JP2018538244A5 (cg-RX-API-DMAC7.html)
AU2019355574A1 (en) PI3K inhibitors and uses thereof
JP6710435B2 (ja) ジピリンホウ素錯体及びこれを含有する医薬
JP5555494B2 (ja) 癌を治療するためのアミノ化ヒドロキシキノリン類誘導体
WO2011154580A1 (es) Nuevos inhibidores de cxcr4 como agentes anti-vih
FI68826B (fi) Foerfarande foer framstaellning av 6,7,8,9-tetrahydro-4h-pyrido(1,2-a)pyrimidin-4-on-derivat
US20200140406A1 (en) Trioxolane agents